S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
All the trading advice you’ve ever received boils down to this (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
All the trading advice you’ve ever received boils down to this (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
All the trading advice you’ve ever received boils down to this (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
All the trading advice you’ve ever received boils down to this (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023

Titan Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTNP)

$0.35
+0.02 (+6.06%)
(As of 11/30/2023 ET)
Compare
Today's Range
$0.34
$0.35
50-Day Range
$0.33
$0.50
52-Week Range
$0.31
$1.09
Volume
3,734 shs
Average Volume
20,741 shs
Market Capitalization
$5.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TTNP stock logo

About Titan Pharmaceuticals Stock (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

TTNP Stock Price History

TTNP Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
TTNP - Titan Pharmaceuticals, Inc.
TTNP Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Provides Shareholder Update
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2021
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTNP
Employees
4
Year Founded
1992

Profitability

Net Income
$-10,210,000.00
Net Margins
-2,021.31%
Pretax Margin
-2,021.31%

Debt

Sales & Book Value

Annual Sales
$560,000.00
Book Value
$0.54 per share

Miscellaneous

Free Float
10,863,000
Market Cap
$5.27 million
Optionable
Optionable
Beta
1.41

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. David Elliot Lazar (Age 32)
    CEO & Principal Financial Officer
    Comp: $726.08k
  • Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 62)
    President, COO & Director
    Comp: $308k
  • Mr. Mike Fritz
    National Sales Director
  • Jennifer Kiernan
    Executive Assistant to CEO & Investor Communications Coordinator
  • Joe Schrei
    Executive Director of Commercial Operations














TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed in 2023?

Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of 2023. Since then, TTNP stock has decreased by 55.3% and is now trading at $0.35.
View the best growth stocks for 2023 here
.

When is Titan Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our TTNP earnings forecast
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 2,021.31% and a negative trailing twelve-month return on equity of 302.61%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals shares reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?
Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TTNP) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -